Determination of dabigatran, rivaroxaban and apixaban using UPLC-MS/MS and comparison with coagulation assays for therapy monitoring

Nederlands Tijdschrift voor Klinische Chemie en Laboratoriumgeneeskunde

Volumn 38, Issue 3, 2013, Pages 142-144

  Schmitz, E M H ^a   Van Den Heuvel, D ^b   Boonen, K ^b   Van Dongen, J L J ^a   Brunsveld, L ^a   Van De Kerkhof, D ^b  

^a EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^b CATHARINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN;

ACCURACY; ARTICLE; CALIBRATION; COAGULATION ASSAY; COMPARATIVE STUDY; DRUG DETERMINATION; DRUG MONITORING; ERYTHROCYTE; FREEZE THAWING; HUMAN; HYDROLYSIS; IN VITRO STUDY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; SIGNAL NOISE RATIO; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION STUDY;

EID: 84892141633     PISSN: 15708306     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Drugwatch.com, Blood thinners Pradaxa, Xarelto have new competitor in eliquis. Last modified on February 22, 2013 (Accessed: April 10 2013) [URL: http://www.drugwatch.com/2013/01/09/fda-approves-eliquis/]
2. Schippers EI. Kamerbrief betreffende nieuwe orale anti-stollingsmiddelen, 13 november 2012.
3. Bassand J. Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents. Europace 2012; 14: 312-324.
4. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 103: 1116-1127.
5. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost. 2012; 107: 985-997.
6. Werkgroep NOACs van de wetenschappelijke verenigingen en Orde van Medisch Specialisten. Leidraad begeleide introductie nieuwe orale antistollingsmiddelen. 2012.
7. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Met Disp. 2008; 36: 386-399.
8. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry, Bioanalytical Method Validation. May 2011.